Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Desferal

(Deferoxamine)

ApprovedSmall molecule

Jazz Pharmaceuticals

Deferoxamine is used to treat iron overload in the body, which can occur from repeated blood transfusions or certain blood disorders. It works by binding to excess iron so the body can eliminate it.[2] Desferal is currently approved and in use across 12 indications[4].[1]

Desferal is one of 264 small molecule programs targeting Breast Cancer. It is currently in Approved.

12

Indications

29

Total Trials

5

Active Trials

263

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Breast CancerApproved

Hepatocellular CarcinomaApproved

Sickle Cell DiseaseCompleted

Beta-ThalassemiaApproved

SurgeryNot yet recruiting

Allogeneic Stem Cell TransplantationTerminated

Leptomeningeal MetastasesRecruiting

Brain IschemiaActive, not recruiting

Subarachnoid HemorrhageRecruiting

Diabetic FootApproved

Breast CancerApproved

Approved

Hepatocellular CarcinomaApproved

Approved

Sickle Cell DiseaseApproved

Completed

Beta-ThalassemiaApproved

Approved

SurgeryPhase 3

Not yet recruiting

Allogeneic Stem Cell TransplantationPreclinical

Terminated

Leptomeningeal MetastasesPhase 1

Recruiting

Brain IschemiaPreclinical

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Recruiting

Diabetic FootApproved

Approved

Showing 10 of 12 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Desferal

Jazz Pharmaceuticals

Blenoxane

Bristol-Myers Squibb

Recombinant Human Endostatin

PPeking University Third Hospital

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Tianeptine

Diuretic

RReprieve Cardiovascular, Inc

Bisphosphonate

Naltrexone/bupropion

Perflutren Lipid Microsphere

IImaRx Therapeutics

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Subarachnoid Hemorrhage

NCT04566991

Phase 1Recruiting

Leptomeningeal Metastases

NCT05184816

Phase 2Recruiting

Sickle Cell Disease

NCT07023666

Q4 2028

Phase 2/3Not yet recruiting

Surgery

NCT07162363

Clinical

Trials by Indication[1]

Sickle Cell Disease3 trials

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Terminated·AApoPharma·Phase 4·NCT02041299·230 enrolled

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00110617·212 enrolled

Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

Recruiting·IInova Health Care Services·Phase 2·NCT07023666·100 enrolled

Thalassemia3 trials

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed·CCarelon Research··NCT00000623·1,000 enrolled

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major

Completed·OOspedale Microcitemico·Phase 4·NCT00800761

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

Completed·RRESnTEC, Institute of Research·N/A·NCT06468423·142 enrolled

Intracerebral Hemorrhage2 trials

High-Dose Deferoxamine in Intracerebral Hemorrhage

Terminated·—·Phase 2·NCT01662895·42 enrolled

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Unknown status·—·Phase 1/2·NCT02367248·180 enrolled

COVID-192 trials

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Unknown status·—·Phase 3·NCT04361032·260 enrolled

Application of Desferal to Treat COVID-19

Unknown status·KKermanshah University of Medical Sciences·Phase 1/2·NCT04333550·50 enrolled

Subarachnoid Hemorrhage2 trials

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial

Unknown status·RRadboud University Medical Center·Phase 1/2·NCT02875262·40 enrolled

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Recruiting·—·Phase 2·NCT04566991·120 enrolled

17 more indications

Surgery1 trial

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

Not yet recruiting·UUniversity of Illinois at Chicago·Phase 2/3·NCT07162363·240 enrolled

Thrombolysis1 trial

Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion

Completed·GGermans Trias i Pujol Hospital·Phase 2·NCT00777140·62 enrolled

Hemochromatosis1 trial

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000595

Pilot Study1 trial

Pilot Study for Patients With Poor Response to Deferasirox

Completed·—·Phase 4·NCT00749515·15 enrolled

Iron Overload1 trial

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Completed· Novartis logo

Novartis·Phase 2·NCT00600938·197 enrolled

Wound Healing1 trial

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers

Not yet recruiting·KKarolinska University Hospital·Phase 2·NCT03137966·174 enrolled

Ischemic stroke1 trial

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Completed·—··NCT05748587·48 enrolled

Oxidative Stress1 trial

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Completed·—·Phase 2/3·NCT04292314·350 enrolled

Combination Therapy1 trial

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Terminated·CCarelon Research·Phase 2·NCT00115349·20 enrolled

Blood Transfusion1 trial

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Completed· Novartis logo

Novartis·Phase 3·NCT00061750·595 enrolled

Allogeneic Stem Cell Transplantation1 trial

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Terminated·—·N/A·NCT00658411·5 enrolled

Chronic Leg Ulcer1 trial

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

Withdrawn·TTauTona Group·Phase 1/2·NCT04058197

Safety and Efficacy1 trial

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Terminated· Novartis logo

Novartis·Phase 2·NCT01459718·32 enrolled

Acute Kidney Injury1 trial

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

Completed·BBrigham and Women's Hospital·Phase 2·NCT04633889·320 enrolled

Red Blood Cell Transfusions1 trial

A Comparative Study to Evaluate the Efficacy and Safety of Irochel (Unani Coded Formulation) for the Management of Transfusion-Induced Iron Overload in Thalassemia Patients in Comparison With Deferoxamine

Completed·HHamdard University·Phase 3·NCT07782931·132 enrolled

Leptomeningeal Metastases1 trial

A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05184816·32 enrolled

Unspecified1 trial

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Unknown status·WWeill Medical College of Cornell University·Phase 1/2·NCT00738413·6 enrolled

Regulatory

FDA Approval Timeline[5]

May 25, 2000

DESFERAL

NDA NDA016267

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Deferoxamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Desferal drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Deferoxamine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Deferoxamine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA016267). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals

Related News